Morgan Stanley Neoleukin Therapeutics, Inc. Transaction History

Morgan Stanley

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$0.68 - $0.91 $208 - $279	307 Added 0.04%	821,972 $682,000
Q1 2023 May 15, 2023	BUY	$0.5 - $0.72 $129,621 - $186,654	259,242 Added 46.09%	821,665 $575,000
Q4 2022 Feb 14, 2023	SELL	$0.4 - $0.55 $12,015 - $16,520	-30,038 Reduced 5.07%	562,423 $286,000
Q3 2022 Nov 14, 2022	SELL	$0.69 - $1.33 $20,997 - $40,473	-30,431 Reduced 4.89%	592,461 $379,000
Q2 2022 Oct 27, 2022	SELL	$0.92 - $2.25 $50,809 - $124,263	-55,228 Reduced 8.14%	622,892 $641,000
Q2 2022 Aug 15, 2022	SELL	$0.92 - $2.25 $50,809 - $124,263	-55,228 Reduced 8.14%	622,892 $641,000
Q1 2022 Oct 27, 2022	BUY	$1.72 - $5.23 $94,992 - $288,842	55,228 Added 8.87%	678,120 $1.27 Million
Q1 2022 May 13, 2022	BUY	$1.72 - $5.23 $134,361 - $408,551	78,117 Added 13.02%	678,120 $1.27 Million
Q4 2021 Feb 14, 2022	BUY	$4.65 - $7.75 $11,601 - $19,336	2,495 Added 0.42%	600,003 $2.89 Million
Q3 2021 Nov 15, 2021	BUY	$6.05 - $9.66 $3.61 Million - $5.77 Million	597,508 New	597,508 $4.32 Million

199K

Ticker NLTX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 42,579,900
Description
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of vario...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.